title: Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the national institutes health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapy.
abstract: Several grading systems have been developed in the bone marrow transplantation setting in attempts to predict survival in patients with chronic graft-versus-host disease (cGVHD). In this study, we evaluated the prognostic value of the National Institutes of Health (NIH) scoring system and investigated for any additional prognostic factors in a series of 171 patients undergoing peripheral blood stem cell transplantation (PBSCT) from matched related donors. The cumulative incidence of cGVHD was 70%; cumulative incidences of mild, moderate, and severe cGVHD were 29%, 42% and 28%, respectively. Overall, 68% of patients were free from immunosuppression 5 years after transplantation. Absence of previous acute GVHD (aGVHD; hazard ratio [HR] = 2; P = .004) and mild cGVHD (HR = 4.2; P = .007) increased the probability of being off immunosuppressive treatment by the last follow-up. Overall survival (OS) at 5 years was 52%. Severe cGVHD, according to the NIH scoring system (HR = 13.27; P = .001) adversely influenced outcome, whereas de novo onset (HR = 0.094; P = .003) had a more favorable impact on survival. The combination of both variables allowed us to identify 4 different subgroups of patients with OS of 82%, 70%, 50%, and 25%. Our findings indicate that the NIH scoring system has some prognostic value in patients undergoing PBSCT and, together with the type of onset, must be considered to predict the possible outcome of patients who develop cGVHD.
authors.affiliation: Department of Hematology, University Hospital of Salamanca Cancer Research Center (CIC/CSIC) of Salamanca and Center of Regenerative Medicine and Cellular Therapy of Castilla y Leon, Spain. Electronic address: pesimo@usal.es.
authors.forename: José A
authors.initials: JA
authors.lastname: Pérez-Simón
authors.affiliation: Department of Hematology, University Hospital of Salamanca Cancer Research Center (CIC/CSIC) of Salamanca and Center of Regenerative Medicine and Cellular Therapy of Castilla y Leon, Spain.
authors.forename: Cristina
authors.initials: C
authors.lastname: Encinas
authors.affiliation: Department of Hematology, University Hospital of Salamanca Cancer Research Center (CIC/CSIC) of Salamanca and Center of Regenerative Medicine and Cellular Therapy of Castilla y Leon, Spain.
authors.forename: Fernando
authors.initials: F
authors.lastname: Silva
authors.affiliation: Department of Hematology, University Hospital of Salamanca Cancer Research Center (CIC/CSIC) of Salamanca and Center of Regenerative Medicine and Cellular Therapy of Castilla y Leon, Spain.
authors.forename: Maria José
authors.initials: MJ
authors.lastname: Arcos
authors.affiliation: Department of Hematology, University Hospital of Salamanca Cancer Research Center (CIC/CSIC) of Salamanca and Center of Regenerative Medicine and Cellular Therapy of Castilla y Leon, Spain.
authors.forename: María
authors.initials: M
authors.lastname: Díez-Campelo
authors.affiliation: Department of Hematology, University Hospital of Salamanca Cancer Research Center (CIC/CSIC) of Salamanca and Center of Regenerative Medicine and Cellular Therapy of Castilla y Leon, Spain.
authors.forename: Fermín M
authors.initials: FM
authors.lastname: Sánchez-Guijo
authors.affiliation: Department of Hematology, University Hospital of Salamanca Cancer Research Center (CIC/CSIC) of Salamanca and Center of Regenerative Medicine and Cellular Therapy of Castilla y Leon, Spain.
authors.forename: Enrique
authors.initials: E
authors.lastname: Colado
authors.affiliation: Department of Hematology, University Hospital of Salamanca Cancer Research Center (CIC/CSIC) of Salamanca and Center of Regenerative Medicine and Cellular Therapy of Castilla y Leon, Spain.
authors.forename: Jesús
authors.initials: J
authors.lastname: Martín
authors.affiliation: Department of Hematology, University Hospital of Salamanca Cancer Research Center (CIC/CSIC) of Salamanca and Center of Regenerative Medicine and Cellular Therapy of Castilla y Leon, Spain.
authors.forename: Lourdes
authors.initials: L
authors.lastname: Vazquez
authors.affiliation: Department of Hematology, University Hospital of Salamanca Cancer Research Center (CIC/CSIC) of Salamanca and Center of Regenerative Medicine and Cellular Therapy of Castilla y Leon, Spain.
authors.forename: Consuelo
authors.initials: C
authors.lastname: Del Cañizo
authors.affiliation: Department of Hematology, University Hospital of Salamanca Cancer Research Center (CIC/CSIC) of Salamanca and Center of Regenerative Medicine and Cellular Therapy of Castilla y Leon, Spain.
authors.forename: Dolores
authors.initials: D
authors.lastname: Caballero
authors.affiliation: Department of Hematology, University Hospital of Salamanca Cancer Research Center (CIC/CSIC) of Salamanca and Center of Regenerative Medicine and Cellular Therapy of Castilla y Leon, Spain.
authors.forename: Jesús
authors.initials: J
authors.lastname: San Miguel
mesh_terms: D017677:Age Distribution; D005260:Female; D006086:Graft vs Host Disease / Q000175:diagnosis / Q000401:mortality*; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects / Q000379:methods; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008107:Liver Diseases / Q000175:diagnosis; D008171:Lung Diseases / Q000175:diagnosis; D008297:Male; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects*; D011237:Predictive Value of Tests; D011379:Prognosis; D015996:Survival Rate
chemical_list: D007166:Immunosuppressive Agents